Factors associated with a strictly undetectable viral load in HIV-1-infected patients

HIV Medicine

Volumn 13, Issue 9, 2012, Pages 568-573

  Martin Blondel, G ^a,b   Saune K ^a,b   Vu Hai, V ^a   Marchou, B ^a,c   Delobel, P ^a,b   Izopet, J ^a,b   Cuzin, L ^a   Massip, P ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

Antiretroviral therapy; HIV 1 RNA; Low level viraemia; Residual viraemia; Viral reservoirs

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; VIRAL LOAD;

EID: 84866179754     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01012.x     Document Type: Article

References (21)

1. Cohen C. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials 2009; 10: 116-124.
2. Verhofstede C, Van Wanzeele F, Reynaerts J, Mangelschots M, Plum J, Fransen K. Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J Clin Virol 2010; 47: 335-339.
3. Havlir DV, Koelsch KK, Strain MC etal. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191: 1164-1168.
4. Bonora S, Nicastri E, Calcagno A etal. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81: 400-405.
5. Doyle T, Smith C, Vitiello P etal. Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 62: 724-732.
6. Gatanaga H, Tsukada K, Honda H etal. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis 2009; 48: 260-262.
7. Haim-Boukobza S, Morand-Joubert L, Flandre P etal. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mL. AIDS 2011; 25: 341-344.
8. Widdrington J, Payne B, Medhi M, Valappil M, Schmid ML. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011; 62: 87-92.
9. Antinori A, Perno CF, Giancola ML etal. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787-1793.
10. Yeh RF, Rezk NL, Kashuba AD etal. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 2009; 53: 2367-2374.
11. Palmer S, Maldarelli F, Wiegand A etal. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 3879-3884.
12. Hofstra L, Mudrikova T, Stam A, Schuurman R, Nijhuis M, Wensing A. Low-level viremia and blips are preceded by positive HIV-1 viral load results below the currently used clinical cut-off. 13th European AIDS Conference. Belgrade, Serbia, 2011 [Abstract PS12/4].
13. Hermankova M, Ray SC, Ruff C etal. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA 2001; 286: 196-207.
14. Garcia-Gasco P, Maida I, Blanco F etal. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61: 699-704.
15. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201-207.
16. Schulze zur Wiesch J, van Lunzen J. Hide and seek ... Can we eradicate HIV by treatment intensification? J Infect Dis 2011; 203: 894-897.
17. Buzon MJ, Massanella M, Llibre JM etal. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
18. Gandhi RT, Zheng L, Bosch RJ etal. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7: e1000321.
19. Mavigner M, Delobel P, Cazabat M etal. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE 2009; 4: e7658.
20. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010; 24: 789-802.
21. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.